XLRN - Acceleron's Sotatercept Trial And Other News: The Good Bad And Ugly Of Biopharma
Acceleron Reports Positive Top-Line Results for PULSAR Trial
Acceleron Pharma, Inc. (XLRN) announced top-line results from its Phase 2 trial testing sotatercept in patients with pulmonary arterial hypertension. The trial involved 106 patients who were randomized to be administered placebo, 0.3 mg/kg of sotatercept, or 0.7 mg/kg of sotatercept subcutaneously every 21 days in combination with stable background PAH-specific therapies. These therapies included mono, double, and triple therapy over a 24-week treatment period.
The phase 2 study was a double-blind, placebo-controlled trial. 35 percent of the 106 patients in the trial had received double background